Reach for Korlym to fight back withSIGNIFICANT IMPROVEMENTS IN GLUCOSE CONTROL

60% of patients achieved a 25% reduction in AUCglucose at Week 24/ET1a,b

Significant improvements in oGTT were seen as early as Week 6 and continued through Week 24.1

Study Design
Graph showing significant improvements in oGTT as early as Week 6 and through Week 24 in the SEISMIC study. Patients with a HbA1c baseline >7% had a significant 1.9% mean reduction at Week 24/ET (n=12).

AUCglucose, area under the curve for glucose; ET, early termination. oGTT, oral glucose tolerance test.

aIn patients with Cushing syndrome and either type 2 diabetes or impaired glucose tolerance.

bThose with a 25% decrease in AUCglucose from baseline to Week 24 were considered responders. This primary efficacy endpoint was considered met if ≥20% of patients were responders.

Early and significant improvements in AUCinsulin

Improvements in AUCinsulin were seen as early as Week 6 and continued through Week 241

Graph showing significant improvements in AUCinsulin at Week 6 and Week 24/ET in the SEISMIC study.

AUCinsulin, area under the curve for insulin.

Error bars in the graph are SD. A combined cohort of patients not treated with insulin.

P<0.001 vs baseline.

†P=0.002 vs baseline.

For more information about Korlym

Contact a Rep
References:
  1. Fleseriu M, Biller BMK, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-2049. doi:10.1210/jc.2011-3350
  2. Korlym Prescribing Information. Corcept Therapeutics, Inc; 2019.